Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020530 | 0.83 | HTR6 (0.40) | PTPN1ALOX5 | |
| SCHEMBL4027251 | 0.80 | PTPN1 (0.47) | PTPN1HPGDALDH1A1 | |
| SCHEMBL6583913 | 0.75 | PTPN1 (0.55) | PTPN1HPGDSMN1; SMN2ALDH1A1PRNP | |
| SCHEMBL4301273 | 0.74 | KDM4E (0.47) | HPGDALDH1A1ALOX5 | |
| SCHEMBL4031173 | 0.74 | CXCR2 (0.37) | PTPN1SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL4024478 | 0.74 | ALOX5 (0.55) | MTNR1AMTNR1BALOX5 | |
| SCHEMBL6582980 | 0.73 | PTPN1 (0.66) | PTPN1ALDH1A1PRNP | |
| SCHEMBL4022725 | 0.72 | KDM4E (0.50) | HPGDALDH1A1 | |
| SCHEMBL4022869 | 0.72 | PTPN1 (0.52) | PTPN1HPGDALDH1A1PRNP | |
| SCHEMBL4023445 | 0.69 | PSEN1 (0.45) | HPGDALDH1A1MTNR1AMTNR1BALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629377-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1397356-B1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-7351730-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060014725-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2006-01-19 | — | — | US | disclosed |
| US-6939886-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH | 2004-12-30 | — | — | US | disclosed |
| US-6800654-B2 | FOR TREATING CONDITIONS RESULTING FROM FIBRINOLYTIC DISORDERS SUCH AS DEEP VEIN THROMBOSIS AND CORONARY HEART DISEASE, AND PULMONARY FIBROSIS. | WYETH | 2004-10-05 | — | — | US | disclosed |
| EP-1397356-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2003000684-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014725-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | TFPI, SERPINE1, F12 | PTPN1 778/4885HPGD 2039/4885SMN1; SMN2 4287/4885 |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | TFPI, SERPINE1, F12 | PTPN1 658/4885HPGD 1899/4885SMN1; SMN2 4516/4885 |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | TFPI, SERPINE1, SERPINC1 | PTPN1 958/4885HPGD 1735/4885SMN1; SMN2 4634/4885 |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | TFPI, SERPINE1, SERPINC1 | PTPN1 902/4885HPGD 1669/4885SMN1; SMN2 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.